June 28, 2002
The cyclooxygenase 2 (COX-2) inhibitor celecoxib may prove useful as short-term, add-on therapy for acute schizophrenia exacerbations, according to results of a double-blind, randomized trial of risperidone with or without celecoxib reported in the June issue of the American Journal of Psychiatry.
“Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone with regard to total schizophrenia psychopathology,” write Norbert Müller, MD, and colleagues from the Psychiatric and Psychotherapeutic Hospital, Ludwig Maximilians University, in Munich, Germany. “Moreover, the fact that treatment with an immunomodulatory drug showed beneficial effects on schizophrenia symptoms indicates that immune dysfunction in schizophrenia is not just an epiphenomenon but is related to the pathomechanism of the disorder.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!